EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 791 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Preparing for the End of the U.S. Public Health Emergency (PHE):... February 13, 2023 Excellence in cancer research nursing: Celebrating innovation during tough times October 7, 2022 This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... October 4, 2019 Load more HOT NEWS Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and... Breathing Amidst Uncertainty
